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Abstract
Background & objectives: The availability of numerous brands of artesunate in our drug market today
places clinicians and pharmacists in a difficult situation of choice of a suitable brand or the possibility
of alternative use. The aim of the present study was to predict the bioequivalence of nine brands of
artesunate tablets marketed in Nigeria using in vitro tests.
Methods: The in vitro dissolution study was carried out on the nine brands of artesunate tablets
using the basket method according to US Pharmacopoeia (USP) guidelines. Other general quality
assessment tests like hardness and disintegration time were also determined.
Results: All the brands tested passed the British Pharmacopoeia (BP) standard for disintegration
time. Only AT2, AT4, AT6 and AT9 passed the standard for hardness. There were significant
differences in the dissolution profiles of the nine brands. All the brands except AT1, however,
released >70% of artesunate within 30 min. Four of the brands AT5, AT6, AT7 and AT8 exhibited
>90% dissolution in <10 min. The other brands AT1, AT2, AT3, AT4 and AT9 (innovator brand)
have calculated similarity factors of 23.8, 59.8, 50, 54.8 and 100.
Interpretation & conclusion: Based on the in vitro tests, AT5, AT6, AT7 and AT8 are considered
bioequivalent and interchangeable, while AT2, AT3 and AT4 are considered bioequivalent and
interchangeable with the innovator brand (AT9). AT1 has very low dissolution rate, which will
likely result in poor bioavailability. The results show the need for constant monitoring of new
brands of artesunate introduced into the drug market to ascertain bioequivalence and conformity
with pharmacopoeia standards.
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Introduction
Widespread resistance of Plasmodium falciparum to
quinoline-based drugs has made the disease situation
difficult to manage in  malaria endemic areas1.
Artemisinin and its derivatives are a major advance
in antimalaria treatment2. These drugs are increas-
ingly used for the treatment of multi-drug resistant P.
falciparum. With the adoption of artemisinin combi-
nation therapy (ACT) by WHO as the first line drugs,
the average consumption of these artemisinin-based
drugs has increased resulting in the influx of numer-
ous brands into the global drug market. Artesunate is
the most widely available and used drug. Oral
artesunate can be used alone or in combination, usu-
ally with mefloquine or amodiaquine3.
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our drug market today places clinicians and pharma-
cists in a difficult situation of choice of a suitable
brand or the possibility of alternative use. Besides,
there are growing concerns that various artesunate
formulations may have different bioavailability and
that development of resistance will accelerate if sub-
optimal doses are used4,5. Despite the considerable
use in Nigeria, there are no reports on the bioavaila-
bility and bioequivalence of the various brands of
artesunate tablets marketed in Nigeria. Hence the
present investigation has been carried out.
Oral artesunate is hydrolysed rapidly back to the
metabolite dihydroartemisinin (DHA), which is in-
trinsically more active as antimalaria agent. Oral
artesunate may, therefore, be considered as mainly a
prodrug for DHA, as this metabolite is the main con-
tributor to the overall antimalaria activity6-8. The
bioavalability of artesunates from different formula-
tions of the drug is thus an important parameter to
assess when comparing the clinical performance of
various brands. Prediction of in vivo bioavailability
in most oral drugs has been shown to depend on the
in vitro dissolution studies9-11.
In the present study, we set out to assess the in vitro
dissolution of nine brands of artesunate tablet mar-
keted in Nigeria. The results of the study will provide
a rationale for the interchangeability or otherwise of
the selected brands with the innovator brand. Other
general quality assessments of the tablets are also
determined.
Material & Methods
A total of nine brands of artesunate designated as
AT1, AT2, AT3, AT4, AT5, AT6, AT7, and AT8 were
compared with the reference drug, AT9. Pure sample
of artesunate was kindly donated by Kunimed Phar-
maceutical Co., Lagos, Nigeria.  UV-Visible PC
Spectrophotometer (Model Unico 2102, U.S.A.),
Mosanto tablet hardness tester (Mosanto, U.K.),
Erweka disintegrating chamber, Erweka DT-D disso-
lution test (Erweka, U.K.) were used for analysis.
Different brands of artesunate studied were selected
based on frequency of prescription, use and availabil-
ity in hospital and community pharmacy shelves.
Drugs were obtained from pharmacies located in four
different major towns in Nigeria. The towns were
selected to ensure adequate geographical spread. All
the brands used were registered by the National
Agency for Food Drug Administration and Control
(NAFDAC) and were manufactured within six
months of the study. A simple analytical procedure
based on UV spectrophotometry was developed and
adopted for quantitation of the drug in solution.
Bioequivalence was assessed based on comparison of
parameters like T50 (50% dissolution time) and T90
(90% dissolution time) and by calculating similarity
factor, f2
12.
Serial diluted solutions of 10, 20, 30, 40, 50, 60 mg%
of artesunate were prepared from a stock solution of
100 mg% in  sodium hydroxide and monobasic po-
tassium phosphate solution (SIF). Absorbance read-
ings were taken at 287 nm using spectro-photometer.
A plot of absorbance vs concentration of artesunate
was made from which the regression equation was
calculated.
The dissolution tests were carried out using the bas-
ket method according to US Pharmacopoeia (USP)
guidelines13, operated at 100 rpm in a dissolution bath
containing SIF, with sink condition maintained at a
temperature of 37 ± 0.5ºC. One tablet chosen ran-
domly from each of the tablets was put into the bas-
ket suspended in the dissolution medium. Samples (2
ml) were withdrawn at intervals for a total of 120 min.
At each withdrawal 2 ml of fresh dissolution medium
was used to replace the withdrawn sample. Each
sample was filtered, diluted and the absorbance read-
ing determined at 287 nm using UV spectrophotom-
eter against the blank, SIF. The concentration was
thereafter determined from the calibration curve of
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In vitro bioequivalence was demonstrated by com-
parison of the dissolution profile after fitting into the
mathematical model, similarity factor, f2. The simi-
larity factor, f2 used as the mathematical model for
comparing the bioequivalence of the nine brands was
calculated using the following formula.
Where, f2 = Similarity factor; n = Number of time points;
R (t) = Mean percent drug dissolved e.g. a reference product;
T (t) = Mean percent drug dissolved of e.g. a test product. Not
more than one mean value of >85% dissolved for each formu-
lation. An f2 value between 50 and 100 suggests that the two dis-
solution profiles are similar12.
all the brands released >90% of the active ingredient
within 10 min.
The calculated similarity factors, f2, for AT1, AT2,
AT3, and AT4 are shown in Table 2. Apart from AT1,
all the other brands fall within the acceptable range
of 50–100.
Table 1. Results of hardness and disintegration time tests
Formulation Hardness Disintegration
(kgf) time (min)
AT1 3.0 ± 0.29* 8.0 ± 0.57*
AT2 5.0 ± 0.58* 5.9 ± 0.03#
AT3 4.5 ± 0.29 0.58 ± 0.006#
AT4 8.5 ± 0.29 7.0 ± 0.28#
AT5 1.65 ± 0.057# 1.15 ± 0.029#
AT6 11.5 ± 0.30 1.0 ± 0.14$
AT7 2.5 ± 0.28* 0.3 ± 0.03#
AT8 3.0 ± 0.57* 4.0 ± 0.14#
AT9 7.0 ± 0.28 15 ± 0.35
*p <0.05; #p <0.01; $p <0.001 all compared with the innovator
brand, AT9; Values are given as mean ± SEM; n = 5.
y = 0.0214x - 0.0125
R
2
= 0.9891
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Fig. 1: Calibration curve of artesunate in SIF
The results of crushing strength and disintegration
time tests were analyzed using Student’s t- test (SPSS
11) and expressed as mean ± SEM. Differences be-
tween the means of the brands and that of the inno-
vator drug, AT9 were considered statistically signifi-
cant at p <0.05.
Results
The nine brands of artesunate tablet showed signifi-
cant variation in crushing strength and disintegration
time (Table 1). Five brands, AT1, AT3, AT5, AT7 and
AT8 have crushing strength values <5 kgf and are
considered suboptimal, while the other brands, AT 2,
AT4, AT6 and AT9 with values >5 kgf are considered
optimal14. All the brands tested disintegrated in <16
min (Table 1). The calibration curve as shown in Fig.
1 has good correlation (R2 = 0.9891).
The dissolution profiles for brands AT1, AT2, AT3,
AT4 and AT9 indicate that all the brands except AT1
released >70% of the active ingredient within 30 min
(Fig. 2a). Similarly, the dissolution profiles of AT5,
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Discussion
Oral artesunate is widely used, very well tolerated
and highly effective antimalaria drug8. Consequently,
several brands have been introduced into the Nigerian
drug market in recent times. This multiplicity of
brands often put clinicians and pharmacists into a
difficult situation of choice, and the possibility of
interchangeability among brands. To prove two or
more drugs (same active ingredient) bioequivalent, a
similarity in the rate and extent to which the drug in
the dosage form becomes available for absorption
need be demonstrated15. Drugs from oral dosage
forms only become available for absorption follo-
wing the process of disintegration and dissolution. In
this study, parameters like T50, T90 and f2
12 derived
from the dissolution profiles of the nine brands of
artesunate were used as estimators for the bioavaila-
bility of artesunate, hence their bioequivalence.
Our results based on the in vitro dissolution show that
significant variation exists in the bioavailability of
artesunate from the nine brands of artesunate tablets.
However, all the brands except AT1 released >70%
artesunate within 30 min and as such passed the
Table 2. Results of some parameters from dissolution
profiles of the nine brands
Formulation T50 (min) T90 (min) Similarity
factor, f2
AT1 30* >120# 23.8
AT2 <10 <40 59.8
AT3 <5 <40 50.0
AT4 <5 <40 54.8
AT5 <5 <10 ND
AT6 <5 <10 ND
AT7 <5 <10 ND
AT8 <5 <10 ND
AT9 <10 <40 100
 *p <0.05; #p <0.01, significantly higher when compared with
the innovator drug (AT9); n = 5; ND = Not determined.
Fig. 2 a & b: Percent release of artesunate with time in SIF
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British Pharmacopoeia16 standard for dissolution test
of uncoated tablets. Four brands, AT5, AT6, AT7 and
AT8 exhibited >90% dissolution in <10 min (Table 2
and Fig. 2b). This high rate of dissolution precludes
any possibility of bioavailability problem resulting
from drug dissolution and hence justifies inter-
changeability among the four brands. In cases where
>85% of the drug is dissolved within 15 min, disso-
lution profiles are usually accepted as similar with-
out further mathematical evaluation12. The other five
brands AT1, AT2, AT3, AT4 and the innovator drug,
AT9, did not meet the criterion of 85% dissolution
and as such were subjected to further mathematical
evaluation to demonstrate bioequivalence. The T50
and T90 values of AT3 and AT4 are similar, while that
of AT2 and the innovator drug, AT9 are similar (Table
2). AT1 has a T50 and T90 values of 30 and >120 min
respectively indicating poor dissolution, hence poor
bioavailability. The result of statistical comparison of
the five brands using similarity factor as estimator,
showed that AT2, AT3 and AT4 are bioequivalent
with the innovator drug, AT9.
An oral dosage form is normally composed of a drug
substance and excipients and the proportion between
them, the type of excipients and the manufacturing
method of the final product are chosen based on the
content, the physicochemical and the bulk properties
of the drug and its absorption characteristics. Taken
as a whole, this gives each product certain dissolution
characteristics, which varies from one brand to the
other.  It is not surprising, therefore, the observed
variation in the in vitro dissolution of the nine brands
of artesunate included in this study. Oral artesunate
may be considered mainly a prodrug for dihydro-
artemisinin (DHA), as the metabolite is the main
contribution to the overall antimalarial activity6,7. The
rate and extent of dissolution in the gut, and hence the
absorption is a very critical step in demonstrating the
bioequivalence, since the absorbed drug molecule
readily converts to DHA.
Comparison of the therapeutic performance of two or
more medicinal products containing the same active
substance is a critical means of assessing the possi-
bility of alternative use between the innovator and
any essentially similar medicinal product12. Our re-
sults so far show that the four brands of artesunate,
AT5, AT6, AT7 and AT8 can be interchanged in clini-
cal settings. More so, AT2, AT3, and AT4 are inter-
changeable with the innovator brand, AT9 based on
the calculated similarity factor.
Variations were also observed in the result of disin-
tegration time and non-official hardness tests. The
disintegration time of all the nine brands, however,
fall within British Pharmacopoeia16 specification of
disintegration time of <15 min. Only AT2, AT4, AT6
andAT9, which have crushing strength of >5 kgf are
considered optimal14. Our result seem to support a
strong correlation between disintegration time and
the rate of dissolution as earlier pointed out by other
workers17, except in one case, AT3, where the drug
showed low disintegration time but not commensu-
rate high dissolution rate.
In conclusion, our results indicate that all the brands
of artesunate tablet included in this study apart from
AT1 seem to have high dissolution rate and hence
very good bioavailability. AT5, AT6, AT7 and AT8
can be considered bioequivalent and interchangeable.
More so AT2, AT3 and AT4 can be considered bio-
equivalent and interchangeable with the innovator
brand, AT9. All the brands apart from AT1 could be
substituted for one another in the therapy of malaria
parasite. This study highlights among other things the
need for constant monitoring of the new products
introduced into our drug market with the view to
ascertain bioequivalence and conformity with phar-
macopoeia standards. There is need, however, to
carry out in vivo studies to further substantiate the in
vitro predictions.
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